RT Journal Article
SR Electronic
T1 Different Timing to Use Bevacizumab in Patients with Recurrent Glioblastoma: Early <em>Versus</em> Delayed Administration
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5877
OP 5881
DO 10.21873/anticanres.12930
VO 38
IS 10
A1 PASQUALETTI, FRANCESCO
A1 GONNELLI, ALESSANDRA
A1 MOLINARI, ALESSANDRO
A1 CANTARELLA, MARTINA
A1 MONTRONE, SABRINA
A1 CRISTAUDO, AGOSTINO
A1 BALDACCINI, DAVIDE
A1 MATTIONI, ROBERTO
A1 DELISHAJ, DURIM
A1 MAZZOTTI, VALENTINA
A1 MORGANTI, RICCARDO
A1 COCUZZA, PAOLA
A1 FABRINI, MARIA GRAZIA
A1 LOMBARDI, GIUSEPPE
A1 RUDÀ, ROBERTA
A1 SOFFIETTI, RICCARDO
A1 PAIAR, FABIOLA
YR 2018
UL http://ar.iiarjournals.org/content/38/10/5877.abstract
AB Background/Aim: In patients with recurrent glioblastoma, the best timing to administer bevacizumab is not well addressed yet. In this study, we reported the results of a monocentric experience comparing the early use of bevacizumab (following the first GBM recurrence) with the delayed administration (following the second or even further GBM recurrences). Materials and Methods: This analysis included 129 glioblastoma patients with a median follow-up of 22.4 months (range=5.26-192 months). Results: The median time lapse from diagnosis of glioblastoma to disease recurrence was 11.6 months; 13.1 for patients treated with deferred administration of bevacizumab and 9.9 for patients with early administration (p=0.047). Bevacizumab progression-free survival with early and delayed use was 3.45 and 2.92 months, respectively (p=0.504). Survival time from the start of bevacizumab was 6.18 months in patients with early administration, and 6.47 in the delayed administration one (p=0.318). Conclusion: Delayed administration of bevacizumab can be considered in selected patients with less aggressive recurrent glioblastoma.